Novo CEO: Weight loss medication may change from lifelong treatment
Novo Nordisk CEO Lars Fruergaard Jørgensen challenges conventional thinking and hints at a future where treatment with weight-loss drugs is not necessarily a lifelong commitment, he tells Danish business daily Børsen.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.